Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13294998 | 0.89 | KDM4E (0.44) | TSHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5107496 | 0.87 | MEN1 (0.40) | TSHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5113898 | 0.87 | ALDH1A1 (0.46) | TSHRGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL14195135 | 0.86 | ALDH1A1 (0.43) | TSHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4848292 | 0.85 | MAPT (0.40) | TSHRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL14195164 | 0.85 | MAPT (0.40) | TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL5107595 | 0.83 | FEN1 (0.49) | NPC1RAB9AGAAMEN1KMT2A | |
| SCHEMBL4858255 | 0.83 | ALDH1A1 (0.43) | MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL5113303 | 0.82 | ALDH1A1 (0.43) | TSHRL3MBTL1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL5139494 | 0.81 | ALDH1A1 (0.51) | GAAALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365200-B2 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365200-B2 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365200-B2 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20060229314-A1 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | MIF, MMP12, MSR1 | TSHR 1114/4885NPC1 1125/4885RAB9A 1591/4885 |
| US-20060229314-A1 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | MIF, MMP12, MSR1 | TSHR 1114/4885NPC1 1125/4885RAB9A 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.